VIENNA, Va., Oct. 26 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM) announced today that it has received over $10 million over the past 60 days through the exercise of warrants by investors to purchase the Company's common stock. These additional funds increased the gross proceeds raised in the last 60 days to approximately $30 million. CEL-SCI plans to use the additional proceeds towards its pivotal Phase III clinical trial with its cancer drug Multikine and to accelerate the development of its LEAPS compound for the treatment of H1N1 hospitalized patients. The Company previously said that it planned to commence its first study in humans aimed at improving the treatment of hospitalized H1N1 patients. The goal to be studied with CEL-SCI's investigational LEAPS H1N1 treatment is to induce an effective anti-H1N1 immune response in patients, without the raging pro-inflammatory cytokine response that can follow the natural response to infection and which may lead to a patient's death. Since the beginning of the year, the Company has raised gross proceeds exceeding $43 million and has eliminated its Series K convertible notes which had an initial principal value of $8.3 million. CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine® which is being readied for a global Phase III trial in advanced primary head and neck cancer. CEL-SCI is also developing a treatment for hospitalized H1N1 patients using it's L.E.A.P.S. technology platform, and expects to soon finish the validation of it's state-of-the-art manufacturing facility in Maryland. When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, lack of regulatory clearance to proceed with clinical trials, an inability to duplicate the clinical results demonstrated in clinical studies that have been completed or that are initiated in the future, timely development of any potential products that can be shown to be safe and effective, unwillingness of regulatory authorities to engage in further regulatory dialogue, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital, and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K/A for the year ended September 30, 2008. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For more information, please visit http://www.cel-sci.com/ DATASOURCE: CEL-SCI Corporation CONTACT: Gavin de Windt of CEL-SCI Corporation, +1-703-506-9460 Web Site: http://www.cel-sci.com/

Copyright